TY - JOUR
T1 - The plant lectin FRIL supports prolonged in vitro maintenance of quiescent human cord blood CD34+CD38(-/low)/SCID repopulating stem cells
AU - Kollet, Orit
AU - Moore, Jeffrey G.
AU - Aviram, Ronit
AU - Ben-Hur, Herzl
AU - Liu, Bian Ling
AU - Nagler, Arnon
AU - Shultz, Leonard
AU - Feldman, Michael
AU - Lapidot, Tsvee
N1 - Funding Information:
Supported in part by grants from the Israel Academy of Science (T.L.) and a Research Career Development Award from the Israel Cancer Research Fund (ICRF) (T.L.), the Balfur Peisner Bone Marrow Cancer Research Fund (O.K), ImClone systems, Inc. (J.M., M.F., R.A.), and NIH grant A130389 (L.S.).
PY - 2000/6
Y1 - 2000/6
N2 - Objective: Ex vivo maintenance of human stem cells is crucial for many clinical applications. Current culture methods rely on optimized combinations of cytokines. Although these conditions provide some level of stem cell support, they primarily induce proliferation and differentiation, resulting in reduced repopulation capacity. Materials and Methods: The recently identified legume lectin FRIL has been shown to preserve human cord blood progenitors up to a month in suspension culture without medium changes. To test whether FRIL also preserves human SCID repopulating stem cells (SRC), we cultured human CD34+ cord blood cells in medium containing FRIL, with or without subsequent exposure to cytokines, and tested their repopulating potential. Results: We report that FRIL maintains SRC between 6 and 13 days in culture. Incubation of CD34+ cells with FRIL results in significantly lower numbers of cycling cells compared with cytokine-stimulated cells. CD34+ cells first cultured with FRIL for 6 days and subsequently exposed to cytokines for an additional 4 days generated significantly more mononuclear and progenitor cells and higher levels of engraftment in NOD/SCID mice compared with CD34+ cells cultured with FRIL alone. Similar results were obtained with CD34+CD38(-/low) cells, including expansion of SRC that were cultured in FRIL followed by cytokine stimulation. Moreover, CD34+ cells precultured with FRIL successfully engrafted primary and more importantly secondary recipients with lymphoid and myeloid cells, providing further support that FRIL maintains SRC for prolonged periods. Conclusion: FRIL's ability to preserve quiescent primitive cells in a reversible manner may significantly expand the time and range of ex vivo manipulations of human stem cells for clinical applications. Copyright (C) 2000 International Society for Experimental Hematology.
AB - Objective: Ex vivo maintenance of human stem cells is crucial for many clinical applications. Current culture methods rely on optimized combinations of cytokines. Although these conditions provide some level of stem cell support, they primarily induce proliferation and differentiation, resulting in reduced repopulation capacity. Materials and Methods: The recently identified legume lectin FRIL has been shown to preserve human cord blood progenitors up to a month in suspension culture without medium changes. To test whether FRIL also preserves human SCID repopulating stem cells (SRC), we cultured human CD34+ cord blood cells in medium containing FRIL, with or without subsequent exposure to cytokines, and tested their repopulating potential. Results: We report that FRIL maintains SRC between 6 and 13 days in culture. Incubation of CD34+ cells with FRIL results in significantly lower numbers of cycling cells compared with cytokine-stimulated cells. CD34+ cells first cultured with FRIL for 6 days and subsequently exposed to cytokines for an additional 4 days generated significantly more mononuclear and progenitor cells and higher levels of engraftment in NOD/SCID mice compared with CD34+ cells cultured with FRIL alone. Similar results were obtained with CD34+CD38(-/low) cells, including expansion of SRC that were cultured in FRIL followed by cytokine stimulation. Moreover, CD34+ cells precultured with FRIL successfully engrafted primary and more importantly secondary recipients with lymphoid and myeloid cells, providing further support that FRIL maintains SRC for prolonged periods. Conclusion: FRIL's ability to preserve quiescent primitive cells in a reversible manner may significantly expand the time and range of ex vivo manipulations of human stem cells for clinical applications. Copyright (C) 2000 International Society for Experimental Hematology.
KW - Cell cycle
KW - FRIL
KW - SCID repopulating stem cells
UR - http://www.scopus.com/inward/record.url?scp=0034045738&partnerID=8YFLogxK
U2 - 10.1016/S0301-472X(00)00163-6
DO - 10.1016/S0301-472X(00)00163-6
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0034045738
SN - 0301-472X
VL - 28
SP - 726
EP - 736
JO - Experimental Hematology
JF - Experimental Hematology
IS - 6
ER -